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CASE PRESENTATION
A 42-year-old man presented to UCLA with a history of chronic
hypokalemia and hypomagnesemia. His medical history was unremarkable
except for occasional cramps in his calves. He had no history of laxative or
diuretic abuse or of vomiting, and he was taking no medications. His
47-year-old brother also had a history of chronic hypokalemia and
hypomagnesemia and severe intermittent muscle cramps. He was being
treated with amiloride and magnesium supplementation. Both parents and
a third brother were asymptomatic and had no electrolyte abnormalities.
Physical examination revealed a well-developed white male in no
distress. His blood pressure was 110/70 mm Hg; heart rate, 72 beats/min;
jugular venous pressure was estimated to be 7 cm; his chest was clear to
auscultation. Cardiovascular examination disclosed a regular rate and
rhythm, and no murmurs, rubs, or gallops; his abdomen was nontender
without hepatosplenomegaly. Neurologic examination revealed cranial
nerves 2-12 intact, no sensory or motor deficit, and no Chvostek or
Trousseau sign. He did not have peripheral edema.
Laboratory values were: serum sodium, 136 mEq/liter; potassium, 2.4
mEq/liter; chloride, 94 mEq/liter; total CO2, 28 mEq/liter; venous pH, 7.47
and PCO2, 38 mm Hg; BUN, 10 mg/dl; serum creatinine, 0.7 mg/dl;
ionized calcium, 1.25 mmol/liter; total calcium, 9.2 mg/dl; phosphorus, 3.2
mg/dl; magnesium, 1.1 mg/dl; supine plasma renin, 16.6 ng/ml/hr; supine
aldosterone, 168 pg/ml; PTH, 13 pg/ml; 1,25(OH)2 vitamin D, 42 pg/ml.
Urine chemistries were: sodium, 64 mEq/liter; potassium, 42 mEq/liter;
chloride, 58 mEq/liter; calcium, 1 mg/dl; magnesium, 4.3 mg/dl; phospho-
rus, 67.4 mg/dl; and creatinine, 81 mg/dl. A diuretic screen was negative.
The patient was discharged on no medications and has remained asymp-
tomatic.
DISCUSSION
DR. IRA KURTZ (Chief, Division of Nephrology, Max Factor
Professor of Medicine, Center for Health Sciences, UCLA
School of Medicine, Los Angeles, California): When Dr. Jay
Stein presented a Nephrology Forum on Bartter’s syn-
drome (BS) in this journal 13 years ago [1], he noted that
‘‘several questions remain to be clarified: Is Bartter’s
syndrome the consequence of a single defect, or rather the
clinical phenotype of a variety of tubular defects? Is the
syndrome caused by a defect in sodium chloride transport
per se or by a primary potassium-wasting state? Are
syndromes associated with magnesium and calcium loss, as
well as potassium wasting, pathophysiologically linked?”
These prescient questions can now be answered with more
certainty because of the recent advances in our understand-
ing of the molecular basis for Bartter’s/Gitelman’s syn-
dromes.
The patient being discussed today presented with the
following electrolyte abnormalities: hypokalemia with renal
K1 wasting (high fractional excretion); a chloride-resistant
metabolic alkalosis, elevated plasma renin, elevated plasma
aldosterone (relative to the serum K1 concentration),
hypomagnesemia with renal magnesium wasting (high frac-
tional excretion), decreased urine calcium excretion, and
normal blood pressure. These findings are compatible with
either diuretic abuse due to thiazide-like diuretics or
Gitelman’s syndrome (GS). Because of the family history
and the negative diuretic screen, a diagnosis of Gitelman’s
syndrome was made. In the absence of marked symptoms
over many years, we elected not to treat the patient’s
electrolyte disturbances.
The patient under discussion has the classic features of
GS [2, 3]. Patients with this disorder are normotensive and
have a chloride-resistant metabolic alkalosis, increased
plasma renin and aldosterone/K1 ratio, hypokalemia, hy-
pomagnesemia, and hypocalciuria. The syndrome was first
described in 1966 by Gitelman et al in three patients, two of
whom were sisters [2]. The metabolic abnormalities in
Gitelman’s syndrome shared many of the features of BS, a
disorder first reported by Bartter et al four years earlier and
with which it has subsequently been frequently confused in
the literature [4]. Interestingly, the first case of BS might
have been reported in 1957, when Rosenbaum and Hughes
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described an infant with hypokalemia, metabolic alkalosis,
polyuria, growth failure, and recurrent episodes of volume
depletion [5]. The patients reported by Bartter et al shared
many of the features of GS in that they had a hypokalemic,
chloride-resistant metabolic alkalosis, with elevated plasma
renin levels and normal blood pressure. Unlike GS, the
patients with BS had a urinary concentrating defect and
growth failure and subsequently were shown to be hyper-
calciuric [6]. Despite these known differences, most clini-
cians fail to distinguish between these syndromes. Indeed, it
appears that most patients reported in the literature with
BS in fact have GS [7].
Clinical features
Bartter’s and Gitelman’s syndromes can be distinguished
clinically (Table 1) as well as on the basis of differences in
divalent cation metabolism [8–14]. In BS, symptoms are
dictated by the patient’s age at presentation. Polyuria and
polydipsia are always present in children and adults with BS
and can be the only presenting symptoms. Most cases of BS
present in neonates [15–21]. Maternal polyhydramnios with
premature labor is a common finding, presumably because
of excessive urine production in utero [6, 21, 22]. Some of
the infants have an appearance typical of BS, including a
prominent forehead, triangular facies with drooping
mouth, and large eyes and pinnae (Fig. 1) [23–25]. Subse-
quent difficulties in the neonate include failure to thrive
and growth retardation [21]. Vomiting, diarrhea, and fever
have been reported, and a variant of neonatal BS has been
described with sensorineural deafness [25]. Neonatal BS
can be diagnosed prenatally by finding elevated amniotic
fluid chloride and aldosterone concentrations [26, 27].
Seyberth and colleagues have suggested that the severe
neonatal form of BS be called the hyperprostaglandin E2
syndrome [17, 28, 29]. Indeed, an increased rate of PGE2
excretion is a common feature in BS [30–33]. Indomethacin
has been used to decrease the incidence of polyhydramnios
in pregnant patients with and without BS, although com-
plications in the neonate, including acute renal failure,
tricuspid regurgitation, and patent ductus arteriosus have
been reported [19, 34–36]. In addition, indomethacin ap-
pears to improve the rate of growth in these children [34].
Given that the neonatal form seems to differ only in
severity from the childhood and adult disorder, the term
neonatal BS rather than hyperprostaglandin E2 syndrome
appears justified.
In contrast to BS, GS is a milder disease and doesn’t
present symptomatically in the neonatal period [7, 37].
Patients with GS are not volume depleted clinically. They
can have a plasma aldosterone concentration that is not
markedly elevated, as in the patient presented today,
because their hypokalemia suppresses adrenal aldosterone
production. Furthermore, patients with GS are often
asymptomatic, or they only have neuromuscular complaints
consisting of intermittent muscle spasms, cramps, or tetany
[2, 3, 37–39]. Polyuria and polydipsia are not a feature of
GS. In a subset of patients with electrolyte abnormalities
indistinguishable from those of GS, arthritis in several
joints due to chondrocalcinosis has been reported both in
sporadic cases [40–43], and recently in a familial form [44].
Divalent cation disturbances in BS and GS
Several differences in divalent cation metabolism allow
the two syndromes to be easily distinguished based on
simple laboratory measurements (Fig. 2). Patients with BS
have fasting hypercalciuria, whereas those with GS have a
low urinary calcium excretion [6, 9–12, 14, 45]. In addition
to hypercalciuria, medullary nephrocalcinosis is usually
present in BS but is always absent in GS. The hypercalciuria
in BS can predate the appearance of overt nephrocalcino-
sis. In addition to hypocalciuria, all patients with GS
characteristically have hypomagnesemia and a high frac-
tional excretion of magnesium [2, 10]. The patient pre-
sented today had a normal Umg/Ucr of 0.05. In GS, urinary
magnesium excretion reflects the dietary intake and only
exceeds the normal excretion rate when patients are ingest-
ing magnesium supplements [2, 10]. In BS, both the abso-
lute urinary calcium excretion and the fractional excretion
rate are increased. Despite the hypocalciuria in GS, the
serum total and ionized calcium concentrations are normal,
as in the patient presented today [10]. Colussi et al also
reported that serum PTH levels are in the low normal
range in GS, possibly because of the inhibitory effect of
hypomagnesemia on PTH secretion [10]. In contrast, hypo-
magnesemia is not a typical finding in BS. A modest or
transient decrease in serum magnesium has been reported
in some neonates with BS. However, these infants generally
are extremely ill, and whether the hypomagnesemia is due
to extrarenal causes (vomiting, diarrhea) has not been
excluded. Hypomagnesemia in adults diagnosed with BS in
most cases is due to the failure to diagnose GS [9, 46]. Patients
with BS and GS also differ in that the former have elevated
1,25(OH)2D levels [8, 10, 12, 47] and PGE2 excretion rates
[30, 31, 33, 48]. The increased serum 1,25(OH)2D in patients
with BS occurs in the presence of normal 25-OHD,
24,25(OH)2D, PTH, and phosphorus levels [47]. The mech-
anism for elevated serum 1,25(OH)2D levels in BS is
Table 1. Clinical differences between Bartter’s and Gitelman’s
syndromes
Neonatal
Bartter’s
syndrome
Adult
Bartter’s
syndrome
Gitelman’s
syndrome
Polyhydramnios 1 2 2
Failure to thrive 1 2 2
Growth retardation 1 2 2
Polyuria 1 1 2
Polydipsia 1 1 2
Muscle cramps/spasm 2 2 6
Chondrocalcinosis 2 2 6
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unknown. Previous studies have shown that PGE2 stimu-
lates the hydroxylation of 25-(OH)D in thyroparathyroid-
ectomized rats and in chick and rat kidney cells [49–51].
Restrepo de Rovetto et al have argued that PGE2 stimu-
lates the activity of 1a-hydroxylase, which results in ele-
vated 1,25(OH) levels in BS [47]. Indomethacin therapy
reduces the elevated 1,25(OH)2D levels, Ca
21 excretion,
and PGE2 excretion in BS [8, 47]. A second unproven
possibility is that the renal calcium leak per se increases
plasma 1,25(OH)2D levels.
Role of PGE in BS/GS
The BS/GS literature is replete with additional metabolic
abnormalities that have contributed to the confusion re-
garding the pathogenesis of these syndromes. Most dis-
puted has been the role of excess prostaglandin excretion in
the pathogenesis of the electrolyte abnormalities [29–32,
52–56]. Indeed 17 years ago, a Nephrology Forum pre-
sented by Dr. Michael Dunn was devoted to the role of
prostaglandins in BS [33]. Patients with GS usually have
normal PGE2 excretion rates [7, 57], although elevated
excretion rates also have been reported in GS (that is, in
patients misdiagnosed as having BS) [9, 58, 59]. Although
cyclooxygenase inhibitors ameliorate some of the electro-
lyte disturbances and growth retardation in BS [34, 60],
these drugs are less effective in GS [57, 61]. Excess PGE2
excretion in BS is thought to be a secondary phenomenon
[37]. This conclusion was reached prior to the description
of the specific transport defects in BS/GS on the basis of the
following considerations: (1) mepacrine, a potent phospho-
lipase inhibitor, inhibits PGE2 excretion without increasing
plasma potassium and decreasing plasma renin [46]; (2)
loop diuretics, which mimic several of the features of BS,
increase PGE2 production and/or excretion [62, 63]; and
(3) hypokalemia is not a feature of prostaglandin-produc-
ing tumors [64].
Fig. 1. Two patients with neonatal Bartter’s syndrome described by Landau et al [25]. Both patients have the typical facial appearance with prominent
forehead, triangular face, drooping mouth, and large eyes and pinnae.
Fig. 2. Approach to the clinical differentiation between Bartter’s syn-
drome and Gitelman’s syndrome based on divalent cation metabolism.
Note that some patients with type-3 BS have a normal urine Ca21/creatinine
ratio.
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Clinical assessment of the tubular transport defects in
BS/GS
Early clearance studies suggested that the transport
defect in BS was located in the diluting segment [65, 66].
Initially this finding was attributed to abnormal thick
ascending limb function, although later studies suggested
that abnormal NaCl transport in the distal convoluted
tubule also resulted in abnormal urine diluting ability in
some patients misdiagnosed with BS and in GS [9, 13, 61,
67–69]. The finding that patients with neonatal BS have a
urine concentrating defect in addition to a diluting defect,
fail to respond normally to furosemide, yet have a normal
response to thiazides, suggested that a transport abnormal-
ity in the thick ascending limb of Henle was involved [70].
Similarly, the finding that patients with GS concentrate
their urine normally, have hypocalciuria, fail to respond
appropriately to thiazide diuretics, and have a greater-than-
normal response to loop diuretics suggested that these
patients have a transport abnormality in the distal convo-
luted tubule [9, 13, 61, 67–69, 71]. We know now that the
mere presence of a diluting defect does not distinguish BS
from GS, since both defective thick ascending limb and
distal convoluted tubule NaCl transport lead to impaired
urine diluting ability [61].
NaCl and calcium transport in the distal convoluted
tubule
The characterization of the NaCl transport processes in
the thick ascending limb of Henle (TAL) and the distal
convoluted tubule (DCT) has proven invaluable in our
understanding of the transport abnormalities in BS and GS.
I will begin with a brief outline of normal DCT transport.
The distal tubule comprises three distinct segments: the
distal convoluted tubule, the connecting tubule, and the
initial cortical collecting duct [72]. Most in-vivo data have
been obtained from rats in which delineation among these
segments is difficult. In-vivo transport studies, and more
recent studies of immortalized mouse distal tubule cells,
have shown that the DCT plays an important role in
electroneutral NaCl absorption and PTH-responsive Ca21
absorption [72, 73]. The molecular basis for electroneutral
NaCl transport in the DCT was defined in 1993, when
Gamba et al isolated a ;3.7 kb cDNA, flTSC (thiazide-
sensitive cotransporter, also known as NCCT (NaCl co-
transporter), that encoded the NaCl cotransporter in floun-
der (Pseudopleuronectes americanus) bladder [74]. A
fragment of flTSC then was used to screen a rat renal
cortical cDNA library; the rat NaCl cotransporter (rTSC1),
a ;4.4 kb cDNA encoding a ;110 kD protein with 12
putative membrane-spanning domains, was isolated and
identified [75]. Injection of oocytes with rTSC1 cRNA
significantly increased Cl2-dependent, thiazide-inhibitable
22Na1 uptake. In-situ hybridization and immunocytochem-
istry studies combined with functional data indicate that the
NCCT gene (human gene mapping workshop approved
symbol SLC12A3) encodes the apical membrane thiazide-
sensitive NaCl cotransporter in the distal convoluted tubule
[76–78]. In the rat kidney, polyclonal antibodies against
rTSC1 intensely label the apical membranes in the distal
nephron beginning in the early distal convoluted tubule and
terminating within the connecting tubule; the intensity of
labeling diminished from early to late sites along the distal
tubule [78]. In addition to the DCT, evidence indicates
NCCT expression in osteoblast-like cells [79] and peri-
pheral blood mononuclear cells [80]. The physiologic role
NCCT plays in these extrarenal sites remains to be deter-
mined.
We have known for three decades that thiazide diuretics
decrease urinary calcium excretion [81]. Micropuncture
and microperfusion experiments identified the distal con-
voluted tubule as the site where thiazides stimulate calcium
absorption [82]. Stimulation of Ca21 absorption has been
attributed to (1) decreased apical Na1 uptake driving
basolateral Na1/Ca21 exchange with subsequent increased
apical Ca21 uptake; and (2) decreased intracellular chlo-
ride concentration, which causes hyperpolarization of the
apical cell membrane and stimulates apical Ca21 uptake via
dihydropyridine-sensitive Ca21 channels [82, 83]. Three
alternatively spliced isoforms of the Na1-Ca21 exchange
gene, NCX1–NACA2, NACA3, and NACA6–have been
identified in these cells derived from the mouse DCT,
which might mediate Na1-dependent Ca21 efflux from the
DCT [84]. The relative role of the basolateral Na1/Ca21
exchange isoforms and Ca21-ATPase in mediating cellular
calcium extrusion is currently unknown; both transporters
are co-expressed with rTSC1 in the late DCT and connect-
ing tubule [78].
Molecular basis for Gitelman’s syndrome
It was an ‘‘annum mirabilis” for this field in 1996, when
Lifton’s group uncovered the molecular basis for GS [85]
and BS [86, 87] and allowed many of Dr. Stein’s questions
to be answered. Simon et al first demonstrated complete
linkage of GS to the NCCT gene locus (SLC12A3) on
chromosome 16q13, and specified GS as an autosomal
recessive disorder with 99% penetrance [85]. The linkage to
chromosome 16q13 has been confirmed by others [88–91].
Simon et al identified a wide variety of mutations distrib-
uted throughout the NCCT gene consistent with loss-of-
function alleles. Additional potential loss-of-function mu-
tations also were reported in 1996 [90, 92]. Missense
mutations are most frequent and are usually localized to
the intracellular domains of the protein rather than to the
extracellular or transmembrane domains. Many of the
patients described thus far are compound heterozygotes.
This finding, together with the documentation of indepen-
dent mutant alleles within the same kindred, suggests that
mutant alleles are not rare. In the Swedish and Italian
populations studied, the prevalence of heterozygotes based
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on phenotypic expression is approximately 1% [14, 85, 93].
Simon et al have estimated a sporadic prevalence of 0.001
and a mutant allele frequency of 1/200 [85].
The patient presented today is a compound heterozygote
(Fig. 3). Two different mutations were detected in the
patient’s NCCT cDNA obtained from his peripheral blood
mononuclear cells. In cDNA derived from the patient’s
maternal allele, exon 24 was deleted and resulted in a
premature stop codon (after amino acid 920). The cDNA
derived from the paternal allele had an additional 119 bp
insertion between exon 3 and exon 4, generating a prema-
ture stop codon (after amino acid 187). The patient’s
genomic DNA had a previously reported 59 splice mutation
in intron 24, GGT 3 GTT maternal allele) [85], and a
previously unreported 39 splice site mutation in intron 3,
CAG 3 CAA (paternal allele), which resulted in the
activation of a nearby cryptic splice site in intron 3 [80].
The severity of symptoms has varied widely in families
with Gitelman’s syndrome. The phenotypic consequences
of the mutations described thus far are unknown. Whether
patients with homozygous frameshift mutations have a
more severe phenotype than do those with homozygous or
compound heterozygous missense mutations remains to be
determined [92]. Interestingly, the patient under discussion
was essentially asymptomatic, whereas his brother, who has
identical mutations in the NCCT gene, had frequent muscle
cramps and spasms. The electrolyte abnormalities in the
brother were essentially the same, that is, serum sodium,
140 mEq/liter; potassium, 2.3 mEq/liter; chloride, 94 mEq/
liter; total CO2, 27 mEq/liter; BUN, 13 mg/dl; serum
creatinine, 1.0 mg/dl; ionized calcium, 1.21 mmol/liter; total
calcium, 9.1 mg/dl; phosphorus, 3.7 mg/dl; and magnesium,
1.1 mg/dl. These findings suggest that other biochemical
abnormalities or psychogenic or environmental factors are
modifying the severity of the symptoms in the two brothers.
Alternatively, a background gene effect could modify the
electrolyte abnormalities and/or symptoms in patients with
identical mutations in the NCCT gene locus. The creation
of knockout mice with various NCCT mutations will be
required to correlate specific mutations with the severity of
specific GS phenotypes (biochemical abnormalities, symp-
toms). In addition, comparing identical mutations in sev-
eral strains of mice will help determine the role of back-
ground genes in altering the phenotypic severity in GS.
In 1979, Bauer et al reported a syndrome with electrolyte
abnormalities identical to GS but which differs from the
classic disorder in that patients have arthritis due to
chondrocalcinosis [40]. As I mentioned earlier, several
sporadic cases have since been described [41–43, 94].
Smilde and colleagues reported a familial form of the
disorder in which 7 affected family members had radiologic
abnormalities involving their wrists, elbows, shoulders,
knees, and symphysis pubis [44]. Magnesium therapy ap-
peared to improve the radiologic appearance of the joint
abnormalities in one patient over a 10-year followup.
Magnesium, a known cofactor in the conversion of pyro-
phosphate to inorganic phosphate, increases the solubility
of calcium pyrophosphate in vitro [95]. However, if hypo-
magnesemia is causally related to the arthritis in these
patients, it is unclear why most patients with GS and
patients with other hypomagnesemic disorders don’t have
chondrocalcinosis. Whether a separate gene locus accounts
for this syndrome or whether background genes alter the
typical GS phenotype is unknown. The gene for a separate
Fig. 3. Predicted amino acid sequence of paternal (F) and maternal (M) NCCT polypeptides in the presented patient with GS. Messenger RNA was
isolated from peripheral blood mononuclear cells obtained from normals and from the patient under discussion with GS. Following reverse transcription
with AMV reverse transcriptase, NCCT cDNA was amplified by PCR and sequenced. Genomic DNA from the patient and his parents also was
sequenced to determine the inheritance of each allele. Two different mutations were detected in the patient’s NCCT cDNA (compound heterozygote).
The cDNA from the patient’s paternal allele had an additional 119 bp insertion between exon 3 and 4, generating a predicted premature stop codon
after amino acid 187. In cDNA from the maternal allele, exon 24 was deleted, resulting in a predicted premature stop codon after amino acid 920.
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familial form of chondrocalcinosis associated with intermit-
tent benign seizures and lacking the metabolic abnormali-
ties in GS has been localized to chromosome 5p [96].
Na-K-2Cl cotransport
Clearance studies suggested that the thick ascending
limb (loop of Henle) was the site of the transport abnor-
malities in BS [65]. The characteristics of Na1, K1, and Cl2
transport in the cortical thick ascending limb (cTAL) and
medullary thick ascending limb (mTAL) were first demon-
strated by Rocha and Kokko [97] and by Burg and Green
[98]. Transport studies in intact nephrons and vesicle
preparations have established that the predominant mode
of apical Cl2 absorption is via a furosemide-sensitive
Na-K-2Cl cotransporter [99]. Sodium chloride transport in
the TAL is stimulated by hormones that activate cAMP,
and is inhibited by extracellular Ca21, PGE2, ANF, and
cytochrome P-450 arachidonate metabolites [100]. In 1994,
using a homology-based screening strategy and functional
expression in oocytes, Gamba et al reported the isolation of
a ;4.7 kb cDNA encoding the rat apical Na-K-2Cl
(NKCC2) cotransporter [75]. Payne and Forbush reported
several splice variants in rabbit and mouse kidney, which
they have called NKCC2A, NKCC2B, and NKCC2F [101].
Using PCR, Yang et al have identified a fourth isoform,
NKCC2AF, in rat kidney [102]. These isoforms, which arise
from alternative splicing of cassette exons, result in a
variable 96-bp region located in the second transmembrane
domain. Amplification by PCR of DNA derived from
specific nephron segments revealed segment-specific ex-
pression: the A isoform is expressed in the cTAL, mTAL,
and macula densa; B isoform is expressed in the cTAL and
macula densa; F isoform is expressed in the mTAL and
outer medullary collecting duct (OMCD); and AF is ex-
pressed in the mTAL. Whether these splice variants differ
in their functional characteristics is unknown. Immunoblot
studies show that the major NKCC2 protein is approxi-
mately 150 kD [103]. The topology of this transporter is
similar to NCCT in that both proteins have 12 putative
membrane spanning domains and a central hydrophobic
core region. The overall sequence identity between the
transporters is approximately 50%. Immunocytochemistry
studies have localized the NKCC2 protein to the apical
membrane of the cTAL and mTAL [103]. Other members
of the Na-K-2Cl cotransport family have been cloned,
including the secretory form of the Na-K-2Cl cotrans-
porter, NKCCl, first cloned from dogfish shark rectal gland
[104], and subsequently cloned from human colonic cells
[105] and murine inner medullary collecting duct [106].
More recently, the KCl cotransporter KCCl encoding a
1085 amino acid polypeptide has been cloned [107]. The
KCCl cotransporter shares approximately 25% homology
with other members of the cation-chloride cotransporter
family, is expressed in several tissues, and might represent
the housekeeping form responsible for cellular volume
regulation. In the renal tubule, this transporter might play
a role in basolateral KCl efflux in the rabbit proximal
tubule [108] and cTAL [109].
Mechanism for K1 secretion in the TAL and CCD
Low conductance (30 pS) inward rectifying K1 channels
play a significant role in mediating K1 secretion in the thick
ascending limb (TAL), the cortical collecting duct (CCD),
and various tissues [110]. Luminal K1 efflux in the TAL
ensures an adequate supply of K1 for the apical Na-K-2Cl
cotransporter. In the CCD, K1 secretion by principal cells
ensures adequate renal excretion of dietary K1 intake.
Efforts at identifying channel molecules responsible for
renal K1 secretion resulted in the expression cloning of
ROMK1 (rat outer medulla K1 channel) from rat renal
outer medulla [111], and subsequently in the cloning of
several splice variants in rats (ROMK1-3,6 [112]) and
humans (ROMK1-5 [113]). This divergence of ROMK
mRNA results in the formation of channels with variable
lengths of amino termini. The ROMK channels are mem-
bers of a superfamily of structurally and functionally re-
lated K1 channel proteins [110]. The common functional
properties shared by these channels is their inwardly recti-
fying current voltage relationship. Rectification can be
weak or strong and is due to a voltage-dependent block of
the channel pore by intracellular magnesium and poly-
amines. The ROMK channels expressed in Xenopus oo-
cytes form a weakly inwardly rectifying potassium-channel
current with a single channel conductance of 35–45 pS
[114]. The channel requires magnesium and ATP to open,
exhibits a high open probability, and is inhibited by milli-
molar concentrations of ATP, low intracellular pH, and
arachidonic acid [110, 114]. These properties are compara-
ble to those of the low-conductance potassium channel
electrophysiologically identified in the apical membrane of
thick ascending limb and cortical collecting duct cells [110].
In rats, ROMK1 transcripts are expressed in the CCD,
OMCD, and inner medullary collecting ducts; ROMK2 is
located in the mTAL, cTAL, DCT, connecting tubule
(CNT), and CCD; and ROMK3 is found in the mTAL,
cTAL, DCT, and CNT [115, 116]. No information exists
regarding isoform distribution in the human nephron. No
functional differences have been found thus far in human
ROMK1-5 when expressed in Xenopus oocytes [117]. The
ROMK2 potassium channel and the cystic fibrosis trans-
membrane regulator (CFTR) can form a complex, and
co-expression of ROMK2 and CFTR increases the sensi-
tivity of ROMK2 to the K1 channel inhibitor glibenclamide
[118]. However, it has been suggested that the ROMK6
isoform is more likely to associate with CFTR and form the
epithelial ATP-sensitive potassium channel, at least in the
rat [112].
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Mechanism for basolateral Cl2 transport in the TAL
Chloride is absorbed across the basolateral membrane of
the TAL in part via chloride channels [119]. Three struc-
tural classes of chloride channels have been described: (1)
CFTR (cystic fibrosis transmembrane regulator); (2) gly-
cine and GABAA receptors; and (3) the CLC family of Cl
2
channels [120]. It is the last group of chloride channels that
plays an important role in mediating basolateral Cl2 trans-
port in the TAL. Jentsch et al identified the first of the
voltage-gated CLC genes (C1C-0) by expression cloning
from the marine ray Torpedo marmorata [121]. Nine CLC
family members (ClC-1 through ClC-7, ClC-Ka and ClC-
Kb) are known to play a role in transport, volume regula-
tion, and muscle and neuronal excitability in many tissues.
ClC-Ka and ClC-Kb are expressed exclusively in the human
kidney [122, 123]. Expression of ClC-Ka, ClC-Kb, and the
rat homologues ClC-K1 and ClC-K2 has been localized by
RT-CR in various nephron segments. The precise localiza-
tion throughout the nephron of these ClC chloride chan-
nels at the protein level is currently unknown [122, 124,
125].
Molecular basis for Bartter’s syndrome: mutations in
NKCC2, ROMK, and ClC-Kb
Simon et al demonstrated linkage to the NKCC2 gene
locus (SLC12A1) in 9 patients from five families with
neonatal BS [86]. The authors mapped the gene to chro-
mosome 15q15-q21 using a (GT)n dinucleotide repeat
sequence. The NKCC2 protein is encoded by 26 exons, with
the coding region spanning 80 kb of genomic DNA. Six
mutations in NKCC2 were identified, including non-con-
servative missense and frameshift mutations. In the five
families studied, all affected offspring were homozygous for
alleles of markers used for genotyping. In four of the five
families, affected individuals were offspring of a consan-
guineous union. The latter finding differs in patients with
GS, who are most often compound heterozygotes and
offspring of a non-consanguineous union, as was the pa-
tient discussed today. A possible explanation for the differ-
ence is that heterozygotes in the population with NCCT
mutations are more common. We now refer to patients
with BS due to NKCC2 mutations as having type-1 BS.
The genetic heterogeneity of neonatal BS was demon-
strated recently (Table 2) [87, 126]. Some patients with
neonatal BS have mutations of the ROMK potassium-
channel gene locus (KCNJ1) on chromosome 11q24. Non-
conservative missense mutations, frameshift mutations, and
mutations predicted to cause premature truncation of the
protein were identified. We refer to patients with ROMK
mutations as having type-2 BS. As I said earlier, 5 ROMK
splice variants have been identified in human kidney,
although their relative distribution in the distal portion of
the nephron is unknown. All 5 isoforms have a common 372
amino acid core encoded by exon 5. The mutations de-
scribed thus far affect exon 5 and involve all ROMK
isoforms. Derst and colleagues analyzed the channel activ-
ity of 5 ROMK channel mutations by mutating wild-type rat
ROMK1 transfected into COS-7 cells [117]. In cells ex-
pressing mutated ROMK1, channel currents were low to
absent. Mutations in the N- or C-terminus had low but
significant channel currents.
Given the importance of ROMK channel activity in
mediating both K1 recycling in the TAL and K1 secretion
in the CCD, one might expect that hypokalemia would be
less severe in patients with BS who have ROMK mutations.
Impaired K1 secretion by the CCD would be predicted to
ameliorate the K1 wasting that occurs because of impaired
TAL function. Furthermore, complete loss of ROMK
function might not affect TAL transport to the same extent
as mutations causing complete loss of function of NKCC2,
because of the presence of 70 ps K1 channels in the TAL,
which mediate approximately 80% of the apical K1 con-
ductance under control conditions [110]. This channel
might partially restore K1 recycling in patients with ROMK
defects. A comparison of patients with BS with NKCC2
mutations (type-1 BS) versus ROMK defects (type-2 BS)
indicates that the difference in the degree of hypokalemia
is an important distinguishing clinical feature in some
patients (Fig. 4). In addition, it would be expected that
patients with type-2 BS would have a lower transtubular
Fig. 4. The severity of hypokalemia in type-1 (NKCC2, e) versus type-2
(ROMK, V) and type-3 (ClC-Kb, ) Bartter’s syndrome mutations.
Mean serum potassium in type-1 BS was 2.2 6 0.24 mEq/liter, 3.3 6 0.08
mEq/liter in type-2 BS, and 2.4 6 0.12 mEq/liter in type-3 BS. The data in
patients with ROMK mutations were obtained from Derst et al [117]. The
data in patients with NKCC2 mutations came from Simon et al [86]. The
data in patients with ClC-Kb mutations were from Ref. 128. * P , 0.001.
Table 2. Genetic differences between Bartter’s and Gitelman’s
syndromes
Clinical syndrome Gene locus Chromosome
Bartter’s syndrome
Type-1 SLC12A1 15q15-q21
Type-2 KCNJ1 11q24
Type-3 CLCNKB 1p36
Gitelman’s syndrome SLC12A3 16q13
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potassium gradient (TTKG) and less of a decrease in
urinary K1 excretion in response to amiloride administra-
tion. However, not all patients with ROMK mutations have
mild hypokalemia [87]. In a study in rats by Wang et al, the
K1 channel blocker U37883A inhibited Na1 and K1
absorption in the TAL and K1 secretion in the CCD; a
natriuresis ensued without a change in urinary K1 excre-
tion [127]. This could be an interesting model for studying
the effect of certain lack-of-function ROMK mutations on
blood and urine chemistries prior to the availability of
ROMK knockout mice.
Simon et al recently reported that mutations in the
CLCNKB gene locus on chromosome 1p36 encoding the
ClC-Kb protein also lead to a BS phenotype (type-3 BS)
[128]. Eleven different mutations including large deletions
and missense and nonsense mutations were characterized
in 17 kindreds. As shown in Figure 3, patients with type-3
BS have more severe hypokalemia than do patients with
type-2 BS, and they have hypokalemia comparable to that
in patients with type-1 BS. Interestingly, none of the
patients with type-3 BS had nephrocalcinosis, and 6 of the
17 index cases had urine Ca21/creatinine ratios in the
normal range. The absence of nephrocalcinosis distin-
guishes these patients from those with NKCC2 or ROMK
defects. Whether patients with CLCNKB mutations have
microscopic nephrocalcinosis detectable by renal biopsy
remains to be determined. Of interest is the discovery that
mutations in another member of the CLC family, CLCN5,
causes X-linked hypercalciuric nephrolithiasis (XLHN)
[129]. Unlike type-3 BS, these patients have nephrocalci-
nosis. The localization of the transport abnormalities in GS
and BS is depicted in Figure 5.
Related uncharacterized syndromes
The literature contains reports of several patients with
normotensive hypokalemic metabolic alkalosis but addi-
tional features that prevent them from being classified as
having GS or BS. These disorders likely are due to different
renal tubular transport defects. Runeberg and coworkers
described a 6-year-old boy with tetany and arthritis in the
knees and ankles [130]. He had hypokalemia, metabolic
alkalosis, normal blood pressure, hypocalcemia, hypercal-
ciuria, a high fractional excretion of magnesium, chondro-
calcinosis, and nephrocalcinosis. Renal biopsy showed jux-
taglomerular cell hyperplasia and interstitial fibrosis. Oral
magnesium therapy slowed the progression of the nephro-
calcinosis and decreased the intra-articular calcifications.
Gu¨llner et al reported 3 siblings, ages 10 to 14 years, who
Fig. 5. Localization of transport abnormalities in Gitelman’s and Bartter’s syndromes.
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presented with mild growth retardation, hypokalemia, met-
abolic alkalosis, normal blood pressure, elevated plasma
renin activity, and resistance to angiotensin II [131, 132].
The serum magnesium was normal (1.51 6 0.06 mEq/liter).
One child had polyuria, polydipsia, and neuromuscular
complaints, whereas the others were asymptomatic. The
PGE2 excretion was elevated in all the patients. The urinary
calcium excretion was not measured. Clearance studies
revealed normal distal fractional Cl2 absorption, and the
renal biopsy showed interstitial fibrosis and abnormalities
restricted to proximal tubules without juxtaglomerular cell
hyperplasia. Mehrotra et al recently described a 44-year-old
man with hypokalemia, metabolic alkalosis, normal blood
pressure, mild renal insufficiency, hypermagnesemia, nor-
mocalcemia, a low fractional excretion of magnesium,
hypocalciuria, glucosuria, and elevated plasma renin activ-
ity and plasma aldosterone levels [133]. Clearance studies
showed a high fractional delivery of Cl2 to the diluting
segment and a high distal fractional reabsorption of Cl2.
The patient’s appropriate response to furosemide and
chlorothiazide administration suggested intact TAL and
DCT function. A renal biopsy was not performed; however,
a clinical diagnosis of chronic interstitial nephritis was
made. The authors postulated a defect in proximal tubule
NaCl absorption. Williams et al reported a neonate whose
prenatal course was complicated by polyhydramnios [18].
The infant, who was volume depleted, required mechanical
ventilation and developed generalized seizures at 6 days of
age, had hypokalemia, hypomagnesemia, metabolic alkalo-
sis, hypophosphatemia with renal phosphate wasting, poly-
uria, hypercalciuria, hypermagnesuria, glucosuria, severe
hyponatremia, and adrenal insufficiency. Nephrocalcinosis
was not present. The infant died at 4 months and autopsy
revealed juxtaglomerular cell hyperplasia and extensive
tubular dilation (primarily of the proximal tubules) with
poorly developed brush borders. The authors suggested
that a proximal tubule defect could account for the elec-
trolyte abnormalities. It is of interest that despite a pro-
posed defect in proximal tubule transport, bicarbonate
absorption in this segment appears to have been spared,
given that the patients are alkalemic rather than having
proximal renal tubular acidosis. Whether mutations in
KCC1 are responsible for any of these uncharacterized
syndromes with abnormal proximal tubule transport is
unknown.
Summary of diagnostic considerations
As I said, patients with Gitelman’s and Bartter’s syn-
dromes differ in their clinical presentation and laboratory
findings (Table 1, Fig. 2). Patients with BS usually present
as neonates; patients with GS present in their teens or as
adults. Second, the predominant symptoms in BS are
polyuria and polydipsia; patients with GS usually complain
of muscle spasm and cramps. The degree of hypokalemia is
equally as severe in patients with GS and those with type-1
BS (NKCC2 defect) and type-3 BS (ClC-Kb defect). Pa-
tients with type-2 BS (ROMK defect) can have less severe
hypokalemia. Differences in divalent cation metabolism
clearly distinguish GS from BS. Patients with GS are
hypomagnesemic and hypocalciuric. In contrast, patients
with BS usually have a normal serum magnesium, are
hypercalciuric, and develop nephrocalcinosis. Interestingly,
patients with type-3 BS fail to develop nephrocalcinosis and
are not uniformly hypercalciuric.
In summary, loss of function mutations in NCCT causes
GS. In this disorder, there is defective NaCl transport in the
distal convoluted tubule. Patients with BS (type-1, type-2,
and type-3) have loss of function mutations in the trans-
porters that are required for the normal absorption of Na1,
K1, and Cl2 in the TAL (NKCC2, ROMK, and ClC-Kb).
QUESTIONS AND ANSWERS
DR. NICOLAOS E. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts): Could
you tell us whether any of the mutated proteins of the
Na-K-2Cl cotransporter or the NaCl cotransporter have
been expressed in cell systems, and whether the in-vitro
findings correlate with disturbed function?
DR. KURTZ: At present, no studies have addressed the
effect of specific mutations in type-1 BS on NKCC2 func-
tion in vitro. Derst et al have analyzed five recently
described ROMK channel mutations causing type-2 BS
[117]. The authors expressed mutated rat ROMK1 in
COS-7 cells and were able to demonstrate the effect of
specific type-2 BS mutations on channel currents. Whether
these in-vitro findings will correlate with a particular clini-
cal phenotype is unknown. The number of patients studied
to date is too small to determine whether the severity of
polyuria, hypokalemia, and hypercalciuria/nephrocalcinosis
correlates with specific mutations. It is becoming increas-
ingly evident that background genes also can alter a given
phenotype, so it might be overly simplistic of us to expect a
close correlation between a specific mutation and the
clinical severity of BS in all patients [134–136]. With regard
to GS, Kunchaparty et al have recently expressed in
Xenopus oocytes the mouse NaCl cotransporter incorporat-
ing a GS mutation (premature stop codon at amino acid
968), which abolished function [137]. In addition recently
we showed that peripheral blood mononuclear cells (ob-
tained from the patient with GS discussed today) lack
chlorothiazide-inhibitable 22Na uptake [80]. Our further
understanding of the physiologic processes in the kidney
that result in the clinical differences between these disor-
ders likely will depend on the creation of knockout mice
with GS and BS phenotypes. This approach also will allow
the role of background genes and several other candidate
genes to be tested.
DR. MADIAS: Could you summarize for us the current
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understanding of genotypic-phenotypic relationships in
these disorders? To what do you attribute the phenotypic
variability between patients with these syndromes? Also,
could you address the abnormalities of heterozygote indi-
viduals?
DR. KURTZ: Mutations in the SLC12A3 gene locus are
the only known cause of Gitelman’s syndrome. Whether
patients with chondrocalcinosis and arthritis as well as with
the electrolyte abnormalities found in GS have SLC12A3
mutations will require further studies. In Bartter’s syn-
drome, because three genes are known to be involved, one
might expect a wider spectrum of clinical and laboratory
abnormalities. In addition, no patients with GS have been
found to have NKCC2, ROMK2, or ClC-Kb defects. Con-
versely, no patients with the clinical features of BS have
NCCT mutations.
You raise the interesting issue of heterozygotes. One
might speculate that these individuals have subtle but
detectable salt wasting and potassium wasting, which gen-
erally is not apparent clinically. It is unknown, for example,
whether in either syndrome heterozygotes have more neg-
ative salt balance when placed on a zero Na1 intake, and
more negative potassium balance when placed on a zero
K1 intake. Studies addressing these issues would be of
interest.
DR. MADIAS: It would be interesting to see in expression
studies whether a mutated protein might cause increase of
function.
DR. KURTZ: It is certainly possible, although as yet
unproven, that certain patients with hypertension have
gain-of-function mutations. This issue is currently an active
area of investigation. Virtually all transport proteins known
to mediate Na1 transport directly or indirectly in the
kidney are being studied as candidate genes for gain-of-
function mutations in patients with idiopathic hyperten-
sion.
DR. DAVID LEE (Chief, Division of Nephrology, Sepulveda
Veterans Administration Hospital, and Professor of Medicine,
UCLA, Los Angeles, California): Could you expand on the
role that prostaglandins play in Bartter’s syndrome? The
neonatal form of Bartter’s syndrome is sometimes called
hyperprostaglandin E syndrome. In addition, do all patients
respond to indomethacin, or only a subgroup?
DR. KURTZ: The role of prostaglandins in BS is contro-
versial. Lu¨thy and colleagues have suggested that, in most
patients with Gitelman’s syndrome, prostaglandin E2 excre-
tion is normal and indomethacin is less effective in correct-
ing the hypokalemia [57]. However, some patients origi-
nally diagnosed with BS in retrospect actually had GS; they
had abnormal prostaglandin excretion and electrolyte ab-
normalities that were ameliorated by indomethacin [46,
67]. In BS, PGE2 excretion usually is increased. As I
mentioned, Seyberth et al suggested that the neonatal form
of the disorder be called the hyperprostaglandin E syn-
drome [29]. Cyclo-oxygenase inhibitors do ameliorate many
of the features of BS, although the electrolyte abnormali-
ties are not completely normalized. Excess PGE2 excretion
in BS can directly inhibit Na-K-2Cl cotransport [100, 138],
and arachidonic acid inhibits ROMK1 channels [139].
These effects would be predicted to exacerbate the under-
lying transport abnormalities in BS. Furthermore, as I
discussed, PGE2 might play a role in increasing 1,25(OH)2-
vitamin D in BS, thereby possibly contributing to the
hypercalciuria and nephrocalcinosis [47]. On the other
hand, Delaney et al have shown that mepacrine, a phos-
pholipase inhibitor, normalized PGE2 excretion in their
patients without altering body weight or plasma potassium
[46]. This finding argues against a role for prostaglandins.
Furthermore, Zusman et al reported a patient with a
prostaglandin-producing renal cell carcinoma who did not
have the electrolyte abnormalities of BS [64].
DR. MADIAS: You referred to other syndromes with high
plasma prostaglandin levels. Normal pregnancy is such a
situation. High prostaglandin levels are associated with
elevated plasma renin and aldosterone, hyporesponsiveness
to vasoconstrictors, and low urinary calcium excretion, that
is, a physiologic model of GS.
DR. KURTZ: The high prostaglandin levels you describe
would be characteristic of BS, whereas hypocalciuria is
indeed reminiscent of GS. It is of interest that when
hypocalciuria occurs in pregnancy, it is usually in the
context of pre-eclampsia [140]. The mechanism does not
appear to be decreased intestinal uptake, and likely it is
mediated by the kidney [141]. Furthermore, in pre-eclamp-
sia, the hypocalciuria is associated with low 1,25(OH)2-
vitamin D levels [142]. Despite elevated urinary aldoste-
rone excretion in pregnancy [143], hypokalemia,
hypomagnesemia, and a chloride-sensitive metabolic alka-
losis rarely are present.
DR. CHARLES KLEEMAN (Attending Physician, West Los
Angeles Veterans Administration Hospital, and Professor of
Medicine, UCLA): What drives the hypereninemic hyperal-
dosteronemic state? What is the fundamental cause of this
state in both GS and BS?
DR. KURTZ: It is currently believed that the elevated
plasma renin activity is due to various degrees of volume
depletion resulting from defective renal NaCl absorption.
This scenario is analogous to that seen in patients taking
diuretics, that is, mild volume depletion in GS and severe
volume depletion in neonatal BS. In many patients, how-
ever, the aldosterone level is not elevated because of the
suppressive effect of concomitant hypokalemia on adrenal
aldosterone production.
DR. MADIAS: Is the ROMK channel expressed outside of
kidney, and are ROMK mutations associated with pathol-
ogy elsewhere?
DR. KURTZ: By Northern analysis, ROMK message has
been detected only in the kidney [113]. However, with more
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sensitive PCR techniques, one can detect ROMK isoforms
in various extrarenal tissues [112, 113]. We do not know
whether functional abnormalities in various ROMK chan-
nels outside the kidney play a role in the manifestations of
type-2 BS.
DR. LEE: You mentioned that the thiazide-sensitive NaCl
cotransporter is located in the distal tubule. Were the
results you reported regarding expression of this trans-
porter in lymphocytes performed at the protein level?
DR. KURTZ: Thus far we have shown by Northern analysis
that a 4.4 kb transcript of the thiazide-sensitive NaCl
cotransporter is present in human peripheral blood mono-
nuclear cells [80]. We also recently demonstrated an ab-
sence of thiazide-inhibitable Na1 transport in cells ob-
tained from 2 patients with GS [80]. In regards to Dr.
Madias’ previous question regarding extrarenal ROMK
expression, one could speculate that the dermatitis re-
ported in some patients with GS [2] is somehow related to
abnormal lymphocyte NaCl cotransport.
DR. ARNOLD FELSENFELD (Attending Physician, West Los
Angeles Veterans Administration Hospital, Professor of Med-
icine, UCLA): Dr. Kurtz, you made the analogy between
the loop diuretics and BS, and you referred to the elevated
calcitriol levels in BS. Does the literature contain data
regarding elevation of calcitriol levels in patients receiving
loop diuretics?
DR. KURTZ: Furosemide increases 1,25(OH)2D in a chick
renal tubule suspension, possibly via prostaglandin E2-
mediated stimulation of 1a hydroxylase activity [62]. In
addition, chronic furosemide administration increases se-
rum PTH, in contrast to thiazides, which decrease PTH
levels [144–146]. I am unaware of any in-vivo data demon-
strating an effect of furosemide on 1,25(OH)2 vitamin D.
Your question addresses the more general issue as to
whether the effects of loop diuretics mirror all the electro-
lyte and metabolic abnormalities of type-1 BS (NKCC2
mutations). One important and as-yet-unresolved finding is
the absence of hypomagnesemia in patients with NKCC2
mutations despite the known inhibitory effect of loop
diuretics on magnesium transport. It is perhaps significant
that magnesium absorption in the thick ascending limb of
Henle’s loop is confined to the cortical portion [147]. Net
magnesium transport in the medullary portion is essentially
zero. Given the known distribution of NKCC2 isoforms
that I discussed, if only those isoforms expressed in the
medullary thick limb (NKCC2F and NKCC2AF) were
mutated in type-1 BS, one might not expect to find abnor-
mal loop magnesium transport, because cortical thick as-
cending limb function would remain unaffected. However,
the NKCC2 mutations described thus far would be ex-
pected to affect the cortical and medullary thick ascending
limb, as do loop diuretics. Therefore, isoform differences
cannot explain the lack of hypomagnesemia in type-1 BS. In
type-2 and type-3 BS, hypomagnesemia would also be
expected.
In GS, the converse question arises. Thiazide diuretics do
not characteristically cause more hypomagnesemia than do
loop diuretics [148]. Therefore why is hypomagnesemia
universally present in GS despite the lack of significant
magnesium absorption in the distal convoluted tubule and
collecting duct? One unproven explanation for the severe
hypomagnesemia in GS is that defective sodium transport
in the early distal convoluted tubule enhances sodium
absorption more distally, resulting in an inhibition of
putative basolateral Na1/Mg1 exchange. It is unclear why
thiazide diuretics don’t cause more severe hypomag-
nesemia; the same inhibition of apical Na1/Mg21 exchange
should occur. Future studies in knockout mice will address
the one or more mechanisms for the lack of hypomag-
nesemia in BS and the presence of hypomagnesemia in GS.
This is one of several unresolved issues that will be the
focus of future investigations: (1) What are the mechanisms
for normal serum magnesium in BS and hypomagnesemia
in GS? (2) Why is 1,25(OH)2 vitamin D elevated in BS? (3)
Can patients with NKCC2, ROMK, and ClC-Kb mutations
be clinically distinguished? (4) Why do patients with type-3
BS not have nephrocalcinosis? (5) Are other transporters
with loss-of-function mutations involved in BS (KCC1)? (6)
Is GS with chondrocalcinosis also due to mutations in the
SLC12A3 gene locus? (7) What are the mechanisms for
differences in clinical manifestations among patients who
are members of the same family?
DR. KLEEMAN: Has active transport of magnesium in the
thick ascending limb of Henle been reported?
DR. KURTZ: Studies of mouse and rabbit cortical thick
ascending limb have shown that magnesium transport is a
passive process driven by the lumen-positive potential
difference [147]. Hormonal stimulation of passive magne-
sium absorption results from increases in transepithelial
voltage and paracellular permeability. Active magnesium
transport has not been reported in the TAL.
DR. MADIAS: I have seen a few patients who, after
gentamicin administration, have persistent hypokalemia,
hypomagnesemia and magnesuria, chloride-resistant meta-
bolic alkalosis, and high renin and aldosterone levels with
normal renal function. Has anyone else here encountered
similar patients?
DR. KURTZ: Many years ago, Keating et al reported
magnesium wasting in approximately 5% of patients
treated with aminoglycosides [149]. The transport abnor-
mality abated weeks to months after the drug was discon-
tinued. Histologically, the proximal tubule is affected, as in
cis-platinum toxicity. However, an isolated proximal tubule
defect would not be expected to result in severe magnesium
wasting. It is possible that aminoglycosides are inhibiting
TAL transport by their ability to bind to the basolateral
Ca21-sensing receptor (CaR) [150].
Reprint requests to Dr. I. Kurtz, UCLA Division of Nephrology, 10833 Le
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